StockpollyBeta
Get App
Delisting riskPopularity #4,665
APUS · AMEX · Biotechnology

Apimeds Pharmaceuticals US (APUS)

Developing a bee-venom knee-osteoarthritis therapy and Bitcoin-treasury infrastructure.

$1.97
vs last close+0.12 (+6.49%)

In millions of USD, except per-share figures

In millionsQ4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue00000000000
Gross profit00000000000
10000032746
Research & development00000011011
100000217115
General & administrative100000217115
Other expenses000000000−80
Operating income−100000−3−2−7−4−6
000000006−31−14
Interest income00000000000
Interest expense00000000013
Other non-operating income00000000−63011
Income before tax−100000−3−2−1−35−20
Net income from continuing operations−100000−3−2−1−35−20
Net income−100000−3−2−1−35−20
EPS, basic−$4.92−$2.57−$3.90−$2.88−$2.70−$3.48−$26.00−$14.00−$0.92−$22.60−$11.77
EPS, diluted−$4.47−$2.34−$3.54−$2.62−$2.46−$3.48−$26.00−$14.00−$0.92−$22.60−$11.77
Weighted average shares, basic—————0——122
Weighted average shares, diluted000000——122
EBITDA−100000−3−2−1−34−17
Depreciation & amortization00000000000
EBIT−100000−3−2−1−34−17